First report 1h ago•Last update 52m ago
Insilico Medicine's ISM8969/HT-001 Approved for Parkinson's Clinical Trials in China
Insilico Medicine and Shenzhen Hengtai Biotechnology's innovative oral NLRP3 inhibitor, ISM8969/HT-001, received clinical trial approval in China for Parkinson's disease.
iWitness comments
No comments yet — be the first to weigh in.